Presentation is loading. Please wait.

Presentation is loading. Please wait.

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Published byChristiana Stewart Modified over 6 years ago

Similar presentations

Presentation on theme: "Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung."— Presentation transcript:

1 Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer  Leow Pay Chin, PhD, Ross A. Soo, MD, Richie Soong, PhD, Sai-Hong I. Ou, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 11, Pages (November 2012) DOI: /JTO.0b013e31826baf83 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 ROS1 signaling pathways. ROS1 engages multiple signalling pathways to exert its transformation activity. PLCγ, MAP kinase, IRS1 (signalling molecule to PI3K), VAV3, STATS, cytoskeleton and cell-to-cell interaction (β-integrin, tensin, α-, β-, Δ-catenin, N-catenin) proteins can interact with ROS1, and phospohorylation of these proteins by ROS1 can lead to activation of the respective oncogenic pathways. ROS autophosphorylation sites are docking sites for the tyrosine phosphatases SHP-1 and SHP, Src-homology 2 domain-containing phosphatase; ROS1, c-ros oncogene 1, receptor tyrosine kinase c-ros oncogene 1, receptor tyrosine kinase; PLCγ, phospholipase C, gamma; MAP, mitogen-activated protein kinase; IRS1, insulin receptor substrate 1; VAV3, vav 3 guanine nucleotide exchange factor 1; STATS, signal transducers and activators of transcription-3; PDK1, pyruvate dehydrogenase kinase, isozyme 1; AKT (v-akt murine thymoma viral oncogene homolog 1); mTOR, mechanistic target of rapamycin (serine/threonine kinase); P13K, phosphoinositide-3 kinase; and RHO, rhodopsin. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826baf83) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 ROS1 fusion variants described in non–small-cell lung cancer. The breakpoints of ROS1 are located at exons 32 (e32), 34 (e34), and 35 (e35). All the ROS1 variants harbor the kinase domain whereas the exon 32 breakpoint allows the resulting fusion variants to harbor the TM. In the fusion partners, orange and dark green represent coiled-coil and transmembrane domains, respectively. TM, transmembrane domain; and PD2,. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826baf83) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung."

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.

The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
by Rogelio Zamilpa, and Merry L. Lindsey

by Rogelio Zamilpa, and Merry L. Lindsey
Molecular regulation of mast cell activation

Molecular regulation of mast cell activation
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
cMET Exon 14 Skipping: From the Structure to the Clinic

cMET Exon 14 Skipping: From the Structure to the Clinic
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Kinase inhibitors: Vice becomes virtue

Kinase inhibitors: Vice becomes virtue
Signaling molecules as therapeutic targets in allergic diseases

Signaling molecules as therapeutic targets in allergic diseases
Volume 150, Issue 3, Pages (September 2018)

Volume 150, Issue 3, Pages (September 2018)
Anna F. Farago, MD, PhD, Long P

Anna F. Farago, MD, PhD, Long P
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Similar presentations

Ads by Google